Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

NCT07808112 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT07808112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07808112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label, Randomized-Controlled Trial of CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2031
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft -versus-host-disease